In cancer-related breakthrough dosing, what is the typical approach to dosing for breakthrough episodes?

In cancer-related breakthrough dosing, what is the typical approach to dosing for breakthrough episodes?

• A. Short-acting or immediate-release opioids prescribed for breakthrough episodes; 5–15% of total daily opioid dose per episode; adjust to pain severity and duration.
• B. Use only long-acting opioids; no breakthrough dosing.
• C. Increase baseline dose by 50% and ignore breakthrough events.
• D. Use non-opioid analgesics exclusively.

Answer: (A)